Evaluation of Tumor Infiltrating Lymphocytes in Advanced or Metastatic Triple-Negative Breast Cancer Patients

The primary objective of this study is to evaluate the efficacy of **tumor infiltrating lymphocytes (TILs)** in the treatment of **advanced or metastatic triple-negative breast cancer**. This is clinically relevant as triple-negative breast cancer is a particularly aggressive form of breast cancer with limited treatment options, and TILs may offer a novel therapeutic approach. No secondary objectives are provided in the available data.

The clinical trial involves participants diagnosed with **advanced or metastatic triple-negative breast cancer**. The study population includes both male and female subjects, with an age range spanning from young adults to older adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria for the trial population, as well as any relevant lifestyle considerations such as diet, physical activity, or habits, have not been disclosed. Key inclusion or exclusion criteria are also not specified in the available data.

The clinical trial is designed to evaluate the treatment of **advanced or metastatic triple-negative breast cancer** using tumor infiltrating lymphocytes (TILs). This study is structured as a Phase 1 trial, which typically focuses on assessing the safety, tolerability, and optimal dosing of the investigational treatment. The trial is expected to span from June 21, 2021, to June 21, 2026, encompassing a comprehensive evaluation period. Participants will be involved in a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria are assessed. This is followed by multiple follow-up visits, which are scheduled to monitor the participants' response to the treatment and any potential side effects. The trial concludes with an end-of-study visit, where final assessments are conducted to gather data on the treatment's efficacy and safety.

The expected length of participant involvement in the trial is contingent upon the individual response to the treatment and the overall study timeline. Participants may be subject to early termination from the study if they experience adverse effects that compromise their safety, if they withdraw consent, or if they do not comply with the study protocol. The trial employs a randomized, controlled design to ensure the reliability and validity of the results, although specific details regarding blinding are not provided. The study aims to contribute valuable insights into the potential benefits and risks associated with TIL therapy in this patient population, ultimately informing future research and clinical practice.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date for the trial is June 21, 2021, with an anticipated end date of June 21, 2026. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, Phase 1 trials typically involve initial assessments of pharmacokinetics and pharmacodynamics, which may include measuring **biomarker** levels or other relevant physiological responses. The trial will adhere to a predefined schedule for data collection and analysis, ensuring systematic evaluation of the investigational product's effects. The methods and tools for efficacy assessment will be aligned with standard clinical trial protocols, although specific instruments or scales are not specified in the available data.